Sagimet Biosciences Inc. - Series A Common Stock — Balance Sheet (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

News

Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Sagimet Biosciences Prices $115M Offer Of 8,750,010 Shares And Warrants At $10.00/Unit

Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink

Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE...

Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher